Menu Search
Equities

Fluicell AB

5J9:MUN

Fluicell AB

Actions
  • Price (EUR)0.0116
  • Today's Change0.00 / 0.00%
  • Shares traded10.00k
  • 1 Year change-38.88%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Company’s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.

  • Revenue in SEK (TTM)1.30m
  • Net income in SEK-27.16m
  • Incorporated2012
  • Employees11.00
  • Location
    Fluicell ABFlojelbergsgatan 8CMOELNDAL 431 37SwedenSWE
  • Phone+46 313607481
  • Websitehttps://fluicell.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.